Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2014

View Archived Issues

Phase II results on cediranib in advanced biliary tract cancer

Researchers identify novel polymorphism associated with the risk of miscarriage

Synthetic Biologics and Enterome Bioscience collaborate on microbiome research

FDA grants orphan drug status to Afinitor in DLBCL

Edison Pharmaceuticals obtains FDA orphan drug designation for Leigh syndrome candidate

Isis Pharmaceuticals earns milestone payment for start of phase I ISIS-AR-Rx study

BrainStorm Cell Therapeutics initiates preclinical studies of stem cell therapy in autism

Nymox Pharmaceutical reports new safety study data for NX-1207

Lilly reports topline results from phase III trial of ramucirumab

Amgen presents first-in-human results for AMG-780

High-affinity SV2A PET tracer [11C]UCB-J shows promise in animal models

VGX-100 shows promise as monotherapy or as combination with bevacizumab in first-in-human trial

X-Chem and Pfizer form multi-target collaboration

Beactica enters into drug discovery collaboration with Medivir

AstraZeneca inlicenses Synairgen's SNG-001

University of Pennsylvania researchers gain access to SomaLogic's SOMAscan proteomics platform

Tipelukast shows promise in pulmonary fibrosis model

Genomic Health reports topline results from independent validation study

Chinese company reports discovery of H+/K+-ATPase inhibitors

U.S. investigators patent new compounds for diabetes and obesity

Adelaide Research and Innovation synthesizes novel calpain inhibitors

Northwest Biotherapeutics reports data from phase I/II trial of DCVax-Direct

IRM and Novartis report synthesis of compounds for malaria

Bayer patents detail novel CDK9/CycT1 inhibitors

Phase III data: efficacy of fluticasone furoate/vilanterol improved by adding umeclidinium in COPD

Ruthigen to begin human trials of RUT-58-60 in the U.S.

FDA approves Gadavist as a contrast agent for the evaluation of breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...